About the Author
My name is Mark Senak. I’m a lawyer and I work at the international communications firm FleishmanHillard in New York. For the past several years, I have been consulting with pharmaceutical and biologic companies that are engaged in the process of bringing new drugs to market. I have also worked extensively with an array of medical societies and patient organizations providing strategic communications counsel and media training.Stay Connected
My Profile
I am an authority on regulatory aspects of communications and medical products, with particular emphasis on pre-approval communications; strategist to help pharma and biotech companies prepare best case for advisory committee approval; and counselor in issues and crisis management. I am a frequent speaker on various aspects of same - drug development, promotion, reimbursement and new media in a highly regulated environment. Author of books, newspaper and magazine pieces related to drug marketing and promotion as well as HIV specialty pieces. And of course... blogger!About This Blog
Eye on FDA is published by Mark Senak of FleishmanHillard’s New York office. The thoughts and ideas in this blog and postings are strictly my own and are not screened by my employer. Everything posted on this blog is my personal opinion and does not necessarily represent the views of FleishmanHillard or its clients.
Posts by Date
March 2024 M T W T F S S 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 Twitter List
Legislative Tracking Tools
Category Archives: Pricing and Value
Clouds on the Horizon, Part 2
On Friday, I discussed the fact that there are some clouds on the horizon for the image of the pharmaceutical industry as the Medicare Drug Benefit matures. Today, I’m looking further out on the horizon. The Pharmaceutical Research and Manufacturers … Continue reading
Posted in Marketing, Pricing and Value
Comments Off on Clouds on the Horizon, Part 2
Generics and Pricing
I almost missed this from the FDA. It is common knowledge that generic drugs usually mean a lower price for a chemical therapy. That is why the Hatch-Waxman Act exists. However, a study released by the FDA on April 4, … Continue reading
Posted in Pricing and Value
Comments Off on Generics and Pricing
A Presidential Call for Transparency in Healthcare
Recently the President has been calling for more transparency in healthcare pricing. Initially he is talking about how hospitals and healthcare plans operate. But as the realities of Medicare Part D begin showing themselves, that call may broaden to the … Continue reading
Posted in Pharma Industry Image, Pricing and Value
Comments Off on A Presidential Call for Transparency in Healthcare